Researchers Developing Drug Delivery Patches to Manage Pain Without Addiction Risk

Researchers Developing Drug Delivery Patches to Manage Pain Without Addiction Risk

Everybody occasionally experiences pain. Generally, pain is manageable with over-the-counter medications, or no medication at all. But when pain is acute and severe, such as after an injury or surgery, stronger pain medication may be required. And for chronic pain, such as from neck and back disorders, the long-term use of opioids to subdue pain can become addictive.

Most narcotics are administered orally or by injection, which means these drugs travel through the bloodstream, affecting the entire body, not only the pain site. This can cause side effects such as gastrointestinal problems, sleeplessness, low blood pressure and even liver damage. It also can lead to physical dependency.

About 39.5 million adults complain of daily pain, and at least 2 million people in the United States are addicted to prescription pain medications. In 2015, more than 33,000 people died by opioid overdose, many as illicit users who were first exposed to opioid drugs for treatment of acute or chronic pain.

There must be a better way.

Three University of Virginia researchers are working toward an innovative solution for treating lower back pain after surgery and for chronic back pain. They are developing drug delivery patches that would be worn on the skin, like a bandage, to deliver non-addictive pain medicine directly to the site of pain, rather than systemically via pills or injections. The work builds on UVA’s expertise in orthopedics and pain management – and the engineering of very thin and flexible sensors and circuits.

“We want to relieve pain for patients while also reducing the use of potentially addictive opioids,” orthopedic surgeon Dr. Joshua Li said. “Our goal is to help patients effectively participate in managing their own pain without fear of becoming dependent on medications.”

Li is a spine surgeon who also conducts pain research. He works daily to alleviate his patients’ lower back pain before, during and after surgery, and is well aware of the opioid addiction problem in the U.S. and the need to keep patients comfortable without creating dependency.

Li is working with mechanical engineer Baoxing Xu, an expert at developing skin sensors and devices that precisely control the flow of microfluids, including medications, and with Jin Li, a researcher in orthopedic surgery. Together they are taking the concept of a commercially available product – lidocaine pain relief patches – to a new level.

Lidocaine is a non-addictive pain killer that works topically by blocking pain sensors below the skin. Current lidocaine patches simply release medication to a pain site through skin absorption. But there is no control over when or how much medicine is released, and some of it is not effectively absorbed by the skin.

The UVA researchers believe they have found a way to improve on these patches in a big way by incorporating dissolvable and minimally invasive microneedles below the surface of the patch to painlessly release controllable flows of medicine, combined with temperature sensors and micro-heaters that would create a warm, soothing effect that also alleviates pain. Relief would come within about 15 minutes.

“We already have experience developing very thin, skin-like sensors and micro-heaters,” Xu said. “This new device would bring together several technologies working as one to manage the flow of medication.”

The team proposes to add a button or other control mechanism to their patch that would allow patients to manipulate the release of medication based on pain level, while never having to worry about overdosing or developing an addiction.

“This device would allow us to treat back pain directly at the site of the pain in a controlled manner while bypassing the bloodstream and the liver,” Li said. “We think this could be the solution patients need to safely manage their pain.”

The researchers currently are planning fundamental efficacy studies and believe their technology could be ready for use in clinical trials within about five years.

This project is funded by a seed grant from UVA’s Center for Engineering in Medicine

Media Contact

Fariss Samarrai

University News Associate Office of University Communications